311 related articles for article (PubMed ID: 32767235)
1. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma.
Wedekind MF; Cripe TP
Adv Exp Med Biol; 2020; 1258():77-89. PubMed ID: 32767235
[TBL] [Abstract][Full Text] [Related]
2. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
Morales-Molina A; Gambera S; Leo A; García-Castro J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic viruses for potential osteosarcoma therapy.
Hingorani P; Sampson V; Lettieri C; Kolb EA
Adv Exp Med Biol; 2014; 804():259-83. PubMed ID: 24924179
[TBL] [Abstract][Full Text] [Related]
4. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
5. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.
Martinez-Velez N; Laspidea V; Zalacain M; Labiano S; García-Moure M; Puigdelloses M; Marrodan L; Gonzalez-Huarriz M; Herrador G; de la Nava D; Ausejo-Mauleon I; Fueyo J; Gomez-Manzano C; Patiño-García A; Alonso MM
Mol Cancer Ther; 2022 Mar; 21(3):471-480. PubMed ID: 34965961
[TBL] [Abstract][Full Text] [Related]
6. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
7. Naturally oncolytic viruses.
Roberts MS; Lorence RM; Groene WS; Bamat MK
Curr Opin Mol Ther; 2006 Aug; 8(4):314-21. PubMed ID: 16955694
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
9. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract][Full Text] [Related]
10. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
11. Handling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.
Cuddington B; Verschoor M; Mossman K
J Vis Exp; 2014 Nov; (93):e52232. PubMed ID: 25490047
[TBL] [Abstract][Full Text] [Related]
12. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.
Cassady KA; Haworth KB; Jackson J; Markert JM; Cripe TP
Viruses; 2016 Feb; 8(2):. PubMed ID: 26861381
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?
Tassone E; Muscolini M; van Montfoort N; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():141-148. PubMed ID: 32859494
[TBL] [Abstract][Full Text] [Related]
14. Evolving gene therapy approaches for osteosarcoma using viral vectors: review.
Witlox MA; Lamfers ML; Wuisman PI; Curiel DT; Siegal GP
Bone; 2007 Apr; 40(4):797-812. PubMed ID: 17189720
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.
Garcia-Moure M; Martinez-Vélez N; Patiño-García A; Alonso MM
J Bone Oncol; 2017 Nov; 9():41-47. PubMed ID: 29226089
[TBL] [Abstract][Full Text] [Related]
17. Unleashing the therapeutic potential of oncolytic viruses.
Bommareddy PK; Kaufman HL
J Clin Invest; 2018 Apr; 128(4):1258-1260. PubMed ID: 29504947
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
19. Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.
Vannini A; Leoni V; Campadelli-Fiume G
Adv Exp Med Biol; 2021; 1290():67-80. PubMed ID: 33559855
[TBL] [Abstract][Full Text] [Related]
20. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.
Martínez-Vélez N; Xipell E; Vera B; Acanda de la Rocha A; Zalacain M; Marrodán L; Gonzalez-Huarriz M; Toledo G; Cascallo M; Alemany R; Patiño A; Alonso MM
Clin Cancer Res; 2016 May; 22(9):2217-25. PubMed ID: 26603261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]